2015-09-08 17:44:44 UTC

Ulcerative Colitis: There’s a Spice for That

Sept. 8, 2015

CGH research finds curcumin may improve patient response to mesalamine treatment.

For ulcerative colitis (UC) patients taking the anti-inflammatory agent mesalamine, there may be a way to improve treatment response. Recent research in Clinical Gastroenterology and Hepatology reports that adding curcumin — a spice in the ginger family — to oral and/or topical mesalamine makes the treatment more effective, putting more UC patients in remission.

The researchers performed a multicenter randomized, placebo-controlled, double-blind study of 50 mesalamine-treated patients with active mild-to-moderate ulcerative colitis who did not respond to an additional two weeks of the maximum dose of mesalamine oral and topical therapy.

The addition of curcumin to mesalamine therapy was superior to the combination of placebo and mesalamine at inducing clinical and endoscopic remission, and produced no apparent adverse effects. These findings suggest that curcumin may be a safe and promising agent for treatment of UC. 

Lead study author Nir Salomon shares insights on this research in a blog post on HealthCentral.

More on IBD

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 14, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Advancing Collaborative Approaches in IBD Treatment Decision-Making

March 12, 2018

This is a unique opportunity for payers and providers to gather in the same room to discuss IBD therapy selection, disease monitoring, treatment criteria and access.

Putting Patients First: Digital Health Tools to Empower IBD Patients

Jan. 18, 2018

Discover how advances in digital health can help you monitor and support IBD patients remotely and dynamically, improve face-to-face care, and drive clinical decisions through shared decision-making.